NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Open accessAbstract
Background & aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis.Methods We fed foz/foz and wild-type mice an atherogenic diet for 16weeks, gavaged MCC950 or vehicle until 24weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6weeks and determined the effects on liver fibrosis.Results In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis.Conclusion MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH.Lay summary Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inflammasome activation is a hallmark of MASH livers.
“Inflammasome activation is a hallmark of MASH livers (42)”
From Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2 (2024) · cites this paper as [42]
Inhibition of NLRP3 activation in myeloid cells demonstrated promising anti-fibrotic effects in murine models.
“Similarly, while inhibition of inflammasome signaling, particularly NLRP3 activation in myeloid cells, demonstrated promising anti-fibrotic effects in murine models (142–144)”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [143]
In patients with NASH or animal models, expression of inflammasome components was increased, indicating a potential role in the pathogenesis of liver injury.
“Either in patients with NASH or animal models, the expression of inflammasome components was increased, indicating the potential role in the pathogenesis of liver injury [226,227,288,289,290,291].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [288]
Blockade of NLRP3 signaling with a small molecule inhibitor reduces disease severity in the MCD-Foz/Foz murine NASH model.
“Blockade of NLRP3 signaling with a small molecule inhibitor reduces disease severity in the MCD – Foz/Foz murine NASH model, although the relative contributions of targeting other inflammasome-expressing populations, including myeloid cells, have not been determined (77).”
From Hepatic Stellate Cell-Immune Interactions in NASH (2022) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475 · see citing works
Self-citationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026 · see citing works
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · see citing works
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849 · see citing works
Self-citationInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · see citing works
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338 · see citing works
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077 · see citing works
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039 · see citing works
Wree, A., Eguchi, A., McGeough, M. D., Pena, C. A., Johnson, C. D., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Hepatology · doi:10.1002/hep.26592 · Cited by 945 · see citing works
Self-citationCusi, K. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 912 · see citing works
CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
Leclercq, I. A., Farrell, G. C., Field, J., Bell, D., Gonzalez, F. J., & Robertson, G. R. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8814 · Cited by 763 · see citing works
Self-citationToll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
Miura, K., Kodama, Y., Inokuchi, S., Schnabl, B., Aoyama, T., Ohnishi, H., Olefsky, J. M., Brenner, D. A., & Seki, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.052 · Cited by 741 · see citing works
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
Petrasek, J., Bala, S., Csak, T., Lippai, D., Kodys, K., Menashy, V., Barrieau, M., Min, S.-Y., Kurt-Jones, E. A., & Szabo, G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60777 · Cited by 735 · see citing works
Sterile inflammation in the liver
Kubes, P., & Mehal, W. Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.008 · Cited by 666 · see citing works
Min, H., Kapoor, A., Fuchs, M. A., Mirshahi, F., Zhou, H., Maher, J. W., Kellum, J. M., Warnick, R., Contos, M. J., & Sanyal, A. J. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.004 · Cited by 653 · see citing works
Csak, T., Ganz, M., Pespisa, J., Kodys, K., Dolganiuc, A., & Szabo, G. (2011) · Hepatology · doi:10.1002/hep.24341 · Cited by 645 · see citing works
Inflammasome activation and function in liver disease
Szabó, G., & Petrasek, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.94 · Cited by 600 · see citing works
The Role of Cholesterol in the Pathogenesis of NASH
Ioannou, G. N. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.008 · Cited by 498 · see citing works
Self-citationNLRP3 inflammasome activation is required for fibrosis development in NAFLD
Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1170-1 · Cited by 486 · see citing works
Self-citationA role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation?
Wen, H., Ting, J. P. ‐., & O'Neill, L. A. J. (2012) · Nature Immunology · doi:10.1038/ni.2228 · Cited by 455 · see citing works
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis
Musso, G., Gambino, R., & Cassader, M. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.11.002 · Cited by 410 · see citing works
Hara, H., Tsuchiya, K., Kawamura, I., Fang, R., Hernández-Cuellar, E., Shen, Y., Mizuguchi, J., Schweighoffer, E., Tybulewicz, V. L. J., & Mitsuyama, M. (2013) · Nature Immunology · doi:10.1038/ni.2749 · Cited by 382 · see citing works
Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH
Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.016 · Cited by 368 · see citing works
II. CytochromeP-450 enzymes and oxidative stress
Robertson, G. R., Leclercq, I. A., & Farrell, G. C. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.281.5.g1135 · Cited by 357 · see citing works
Self-citationHepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis
Rooyen, D. M. V., Larter, C. Z., Haigh, W. G., Yeh, M. M., Ioannou, G. N., Kuver, R., Lee, S. P., Teoh, N., & Farrell, G. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.040 · Cited by 345 · see citing works
Self-citationAnimal models of NASH: Getting both pathology and metabolic context right
Larter, C. Z., & Yeh, M. M. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05543.x · Cited by 337 · see citing works
Self-citationNonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes
Ahmed, A., Wong, R. J., & Harrison, S. A. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.029 · Cited by 327 · see citing works
Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis
Ioannou, G. N., Haigh, W. G., Thorning, D., & Savard, C. E. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m034876 · Cited by 256 · see citing works
Self-citationLi, L., Chen, L., Hu, L., Liu, Y., Sun, H., Tang, J. P., Hou, Y.-J., Chang, Y., Tu, Q., Feng, G., et al. (2011) · Hepatology · doi:10.1002/hep.24552 · Cited by 236 · see citing works
Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis
Kakisaka, K., Cazanave, S. C., Fingas, C. D., Guicciardi, M. E., Bronk, S. F., Werneburg, N. W., Mott, J. L., & Gores, G. J. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00301.2011 · Cited by 222 · see citing works
Histones Activate the NLRP3 Inflammasome in Kupffer Cells during Sterile Inflammatory Liver Injury
Huang, H., Chen, H., Evankovich, J. W., Yan, W., Rosborough, B. R., Nace, G., Ding, Q., Loughran, P., Beer–Stolz, D., Billiar, T. R., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202733 · Cited by 217 · see citing works
Maher, J. J., León, P., & Ryan, J. C. (2008) · Hepatology · doi:10.1002/hep.22399 · Cited by 204 · see citing works
Gan, L. T., Rooyen, D. M. V., Koina, M. E., McCuskey, R. S., Teoh, N., & Farrell, G. C. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.024 · Cited by 199 · see citing works
Self-citationCaspase-1 as a Central Regulator of High Fat Diet-Induced Non-Alcoholic Steatohepatitis
Dixon, L. J., Flask, C. A., Papouchado, B. G., Feldstein, A. E., & Nagy, L. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056100 · Cited by 188 · see citing works
Self-citationA fresh look at NASH pathogenesis. Part 1: The metabolic movers
Larter, C. Z., Chitturi, S., Heydet, D., & Farrell, G. C. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06253.x · Cited by 178 · see citing works
Self-citationHigh fat diet feeding results in gender specific steatohepatitis and inflammasome activation
Ganz, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8525 · Cited by 165 · see citing works
Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis
Dixon, L. J., Berk, M. P., Thapaliya, S., Papouchado, B. G., & Feldstein, A. E. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.45 · Cited by 159 · see citing works
Self-citationIoannou, G. N., Rooyen, D. M. V., Savard, C. E., Haigh, W. G., Yeh, M. M., Teoh, N., & Farrell, G. C. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m053785 · Cited by 93 · see citing works
Self-citationCsák, T., Pillai, A., Ganz, M., Lippai, D., Petrasek, J., Park, J., Kodys, K., Dolganiuc, A., Kurt‐Jones, E. A., & Szabó, G. (2014) · Liver International · doi:10.1111/liv.12537 · Cited by 91 · see citing works
Pickens, M., Yan, J. S., Ng, R., Ogata, H., Grenert, J. P., Beysen, C., Turner, S., & Maher, J. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m900022-jlr200 · Cited by 90 · see citing works
Specific inflammasomes in complex diseases
Masters, S. L. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.12.006 · Cited by 89 · see citing works
Self-citationFarrell, G. C., Mridha, A. R., Yeh, M. M., Arsov, T., Van Rooyen, D. M., Brooling, J., Nguyen, T., Heydet, D., Delghingaro‐Augusto, V., Nolan, C. J., et al. (2014) · Liver International · doi:10.1111/liv.12335 · Cited by 85 · see citing works
Self-citationLarter, C. Z., Yeh, M. M., Rooyen, D. M. V., Teoh, N., Brooling, J. T., Hou, J. Y., Williams, J., Clyne, M., Nolan, C. J., & Farrell, G. C. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05996.x · Cited by 85 · see citing works
Self-citationInflammasome biology in fibrogenesis
Ouyang, X., Ghani, A., & Mehal, W. Z. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.03.020 · Cited by 69 · see citing works
Hepatic free fatty acids accumulate in experimental steatohepatitis: Role of adaptive pathways
Larter, C. Z., Yeh, M. M., Haigh, W. G., Williams, J., Brown, S., Bell-Anderson, K. S., Lee, S. P., & Farrell, G. C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.011 · Cited by 67 · see citing works
Self-citationTeoh, N., Ajamieh, H., Wong, H. J., Croft, K. D., Mori, T. A., ALLISON, A. C., & Farrell, G. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104376 · Cited by 56 · see citing works
Self-citationIsolation of Liver Kupffer Cells
Froh, M., Konno, A., & Thurman, R. G. (2002) · Current Protocols in Toxicology · doi:10.1002/0471140856.tx1404s14 · Cited by 51 · see citing works
Innate Immunity and Steatohepatitis: A Critical Role of Another Toll (TLR-9)
Gao, B. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.018 · Cited by 25 · see citing works
Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis
Torres, D. M., & Harrison, S. A. (2015) · Hepatology · doi:10.1002/hep.27680 · Cited by 23 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [2]Farrell GC, McCullough AJ, Day CP, editors. Non-alcoholic fatty liver disease: A practical guide. Chichester: Wiley-Blackwell; 2013.
Cited by
Sorted by citations
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884 · see citing works
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · see citing works
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002 · see citing works
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · see citing works
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885 · see citing works
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237 · see citing works
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941 · see citing works
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease.
Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C., Chevet, É., & Bailly-maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 835 · see citing works
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943 · see citing works
Self-citationMASLD: a systemic metabolic disorder with cardiovascular and malignant complications
Targher, G., Byrne, C. D., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330595 · Cited by 997 · see citing works
New insights into acute pancreatitis
Lee, P. J., & Papachristou, G. I. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0158-2 · Cited by 933 · see citing works
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847 · see citing works
NLRP3 and pyroptosis blockers for treating inflammatory diseases
Coll, R. C., Schroder, K., & Pelegrı́n, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.003 · Cited by 767 · see citing works
Self-citationWen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695 · see citing works
Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease
Masarone, M., Rosato, V., Dallio, M., Gravina, A. G., Aglitti, A., Loguercio, C., Federico, A., & Persico, M. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9547613 · Cited by 648 · see citing works
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 599 · see citing works
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573 · see citing works
Gaul, S., Leszczynska, A., Alegre, F., Kaufmann, B. K., Johnson, C. D., Adams, L. A., Wree, A., Damm, G., Seehofer, D., Calvente, C. J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.041 · Cited by 556 · see citing works
Self-citationThe NLRP3 inflammasome: contributions to inflammation-related diseases
Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., Wang, Z., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00462-9 · Cited by 492 · see citing works
Pierantonelli, I., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 459 · see citing works
Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
Parthasarathy, G., Revelo, X. S., & Malhi, H. (2020) · Hepatology Communications · doi:10.1002/hep4.1479 · Cited by 420 · see citing works
Xu, B., Jiang, M., Chu, Y., Wang, W., Chen, D., Li, X., Zhang, Z., Zhang, D., Fan, D., Nie, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.040 · Cited by 426 · see citing works
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426 · see citing works
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 423 · see citing works
Jin, X., Liu, M., Zhang, D., Zhong, X., Du, K., Qian, P., Yao, W., Gao, H., & Wei, M. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13086 · Cited by 385 · see citing works
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 370 · see citing works
Role of inflammatory response in liver diseases: Therapeutic strategies
Campo, J. A. D., Gallego, P., & Grande, L. (2018) · World Journal of Hepatology · doi:10.4254/wjh.v10.i1.1 · Cited by 348 · see citing works
Molecular Mechanisms That Link Oxidative Stress, Inflammation, and Fibrosis in the Liver
Ramos‐Tovar, E., & Muriel, P. (2020) · Antioxidants · doi:10.3390/antiox9121279 · Cited by 348 · see citing works
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344 · see citing works
Farrell, G., Schattenberg, J. M., Leclercq, I., Yeh, M. M., Goldin, R., Teoh, N., & Schuppan, D. (2019) · Hepatology · doi:10.1002/hep.30333 · Cited by 313 · see citing works
Self-citationWang, Q., Ou, Y., Hu, G., Wen, C., Yue, S., Chen, C., Xu, L., Xie, J., Dai, H., Xiao, H., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14938 · Cited by 310 · see citing works
Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review
Cheng, R., Wu, Z., Li, M., Shao, M., & Hu, T. (2020) · International Journal of Oral Science · doi:10.1038/s41368-019-0068-8 · Cited by 304 · see citing works
Cell Death in Liver Diseases: A Review
Shojaie, L., Iorga, A., & Dara, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249682 · Cited by 299 · see citing works
Role of the Inflammasome in Liver Disease
Ribeiro, M. D. C., & Szabó, G. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032521-102529 · Cited by 280 · see citing works
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Harrison, S. A., Goodman, Z., Jabbar, A., Vemulapalli, R., Younes, Z. H., Freilich, B., Sheikh, M. Y., Schattenberg, J. M., Kayali, Z., Zivony, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.024 · Cited by 260 · see citing works
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
Li, H., Guan, Y., Liang, B., Ding, P., Hou, X., Wei, W., & Ma, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175091 · Cited by 258 · see citing works
Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease
Svegliati‐Baroni, G., Pierantonelli, I., Torquato, P., Marinelli, R., Ferreri, C., Chatgilialoglu, C., Bartolini, D., & Galli, F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.05.029 · Cited by 250 · see citing works
Ma, Q. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000629 · Cited by 255 · see citing works
Inflammasome-Mediated Inflammation in Liver Ischemia-Reperfusion Injury
Jiménez‐Castro, M. B., Cornide‐Petronio, M. E., Gracia‐Sancho, J., & Peralta, C. (2019) · Cells · doi:10.3390/cells8101131 · Cited by 244 · see citing works
P2X7 receptor and the NLRP3 inflammasome: Partners in crime
Pelegrı́n, P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114385 · Cited by 241 · see citing works
Xu, X. J., Yin, D., Ren, H., Gao, W., Li, F., Sun, D., Wu, Y., Zhou, S., Lyu, L., Yang, M., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.016 · Cited by 240 · see citing works
Heyens, L. J. M., Busschots, D., Koek, G. H., Robaeys, G., & Francque, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.615978 · Cited by 243 · see citing works
Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators
Piccinin, E., Villani, G., & Moschetta, A. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0089-3 · Cited by 230 · see citing works
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
Li, H., Yu, X.-H., Ou, X., Ouyang, X.-P., & Tang, C. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101109 · Cited by 230 · see citing works
TNF in the liver: targeting a central player in inflammation
Tiegs, G., & Horst, A. K. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00910-2 · Cited by 231 · see citing works
The NLRP3 inflammasome in traumatic brain injury: potential as a biomarker and therapeutic target
O’Brien, W. T., Pham, L., Symons, G. F., Monif, M., Shultz, S. R., & McDonald, S. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01778-5 · Cited by 228 · see citing works
Lytic cell death in metabolic liver disease
Gautheron, J., Gores, G. J., & Rodrigues, C. M. P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.001 · Cited by 225 · see citing works
“Indeed, activation of IL-1β signalling, downstream of inflammasomes, drives liver inflammation and fibrosis in experimental NASH [93] and amplifies the response of other cytokines [100].”
BackgroundHerbal drug discovery for the treatment of nonalcoholic fatty liver disease
Yan, T., Yan, N., Wang, P., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.017 · Cited by 225 · see citing works
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C. Y., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 225 · see citing works
Hendrikx, T., Porsch, F., Kiss, M. G., Rajcic, D., Papac-Miličević, N., Hoebinger, C., Goederle, L., Hladik, A., Shaw, L. E., Horstmann, H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.004 · Cited by 220 · see citing works
Immunological mechanisms and therapeutic targets of fatty liver diseases
Wang, H., Mehal, W. Z., Nagy, L. E., & Rotman, Y. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00579-3 · Cited by 222 · see citing works
Liu, D., Yang, P.-L., Gao, M., Yu, T., Shi, Y., Zhang, M., Yao, M., Liu, Y., & Zhang, X. (2019) · Clinical science · doi:10.1042/cs20180600 · Cited by 180 · see citing works
NAFLD and NASH: etiology, targets and emerging therapies
Wei, S., Wang, L., Evans, P. C., & Xu, S. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103910 · Cited by 216 · see citing works
Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
Horn, C. L., Morales, A. L., Savard, C. E., Farrell, G. C., & Ioannou, G. N. (2021) · Hepatology Communications · doi:10.1002/hep4.1801 · Cited by 215 · see citing works
Self-citationClonal haematopoiesis and risk of chronic liver disease
Wong, W. J., Emdin, C. A., Bick, A. G., Zekavat, S. M., Niroula, A., Pirruccello, J. P., Dichtel, L. E., Griffin, G. K., Uddin, M. M., Gibson, C. J., et al. (2023) · Nature · doi:10.1038/s41586-023-05857-4 · Cited by 221 · see citing works
Ye, J., Lv, L., Wu, W., Li, Y., Shi, D., Fang, D., Guo, F., Jiang, H., Ren, Y., Ye, W., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01967 · Cited by 211 · see citing works
Zhang, W., Chen, S., Zhou, S., Wu, S., & Wang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643149 · Cited by 208 · see citing works
Zhao, Q., Dai, M., Huang, R., Duan, J., Zhang, T., Bao, W.-M., Zhang, J.-Y., Gui, S.-Q., Xia, S.-M., Dai, C.-T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37459-z · Cited by 213 · see citing works
Hou, X., Yin, S., Ren, R., Liu, S., Yong, L., Liu, Y., Li, Y., Zheng, M., Kunos, G., Gao, B., et al. (2021) · Hepatology · doi:10.1002/hep.31658 · Cited by 223 · see citing works
The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
Cai, J., Zhang, X., & Li, H. (2019) · Hepatology · doi:10.1002/hep.30506 · Cited by 207 · see citing works
Guan, B., Tong, J., Hao, H., Yang, Z., Chen, K., Xu, H., & Wang, A. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.011 · Cited by 208 · see citing works
SCFAs alleviated steatosis and inflammation in mice with NASH induced by MCD
Deng, M., Qu, F., Chen, L., Liu, C., Zhang, M., Ren, F., Guo, H., Zhang, H., Ge, S., Wu, C., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0018 · Cited by 203 · see citing works
NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling
Unamuno, X., Gómez‐Ambrosi, J., Ramírez, B., Rodrı́guez, A., Becerril, S., Valentí, V., Moncada, R., Silva, C., Salvador, J., Frühbeck, G., et al. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0296-z · Cited by 204 · see citing works
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191 · see citing works
FXR agonists in NASH treatment
Adorini, L., & Trauner, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.034 · Cited by 197 · see citing works
The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
Zhan, X., Li, Q., Xu, G., Xiao, X., & Bai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1109938 · Cited by 191 · see citing works
Shi, Y., Su, W., Zhang, L., Shi, C., Zhou, J., Wang, P., Wang, H., Shi, X., Wei, S., Wang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609060 · Cited by 177 · see citing works
Inflammasomes in liver fibrosis
Alegre, F., Pelegrin, P., & Feldstein, A. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1601350 · Cited by 176 · see citing works
Self-citationCholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH
Ioannou, G. N., Subramanian, S., Chait, A., Haigh, W. G., Yeh, M. M., Farrell, G. C., Lee, S. P., & Savard, C. E. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m072454 · Cited by 173 · see citing works
Self-citationPathophysiological mechanisms underlying MAFLD
Kuchay, M. S., Choudhary, N. S., & Mishra, S. K. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.09.026 · Cited by 180 · see citing works
Farrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178 · see citing works
Self-citationCorcoran, S. E., Halai, R., & Cooper, M. A. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000171 · Cited by 179 · see citing works
Self-citationIsmael, S., Nasoohi, S., & Ishrat, T. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2017.5344 · Cited by 173 · see citing works
Inflammasome components as new therapeutic targets in inflammatory disease
Coll, R. C., & Schroder, K. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01075-9 · Cited by 168 · see citing works
Self-citationJia, Y., Wang, F., Guo, Q., Li, M., Wang, L., Zhang, Z., Jiang, S., Jin, H., Chen, A., Tan, S., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2018.09.007 · Cited by 158 · see citing works
Autophagy in hepatic adaptation to stress
Hazari, Y., Bravo-San Pedro, J. M., Hetz, C., Galluzzi, L., & Kroemer, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.026 · Cited by 151 · see citing works
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis
Koh, E. H., Yoon, J. E., Ko, M. S., Leem, J., Yun, J.-Y., Hong, C. H., Cho, Y. K., Lee, S. E., Jang, J. E., Baek, J. Y., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-322509 · Cited by 156 · see citing works
Self-citationPyroptosis in Liver Disease: New Insights into Disease Mechanisms
Wu, J., Lin, S., Wan, B., Velani, B., & Zhu, Y. (2019) · Aging and Disease · doi:10.14336/ad.2019.0116 · Cited by 155 · see citing works
Strategies for Targeting the NLRP3 Inflammasome in the Clinical and Preclinical Space
Schwaid, A. G., & Spencer, K. B. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01307 · Cited by 152 · see citing works
Endoplasmic Reticulum Stress in Metabolic Liver Diseases and Hepatic Fibrosis
Maiers, J. L., & Malhi, H. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1681032 · Cited by 151 · see citing works
Heterogeneity of HSCs in a Mouse Model of NASH
Rosenthal, S. B., Liu, X., Ganguly, S., Dhar, D., Pasillas, M. P., Ricciardelli, E., Li, R. Z., Troutman, T. D., Kisseleva, T., Glass, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.31743 · Cited by 145 · see citing works
Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
Wang, Q., Zhou, H.-M., Bu, Q.-F., Wei, S., Li, L., Zhou, J.-R., Zhou, S., Su, W., Liu, M., Liu, Z., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.02.031 · Cited by 134 · see citing works
IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies
Mirea, A.-M., Tack, C. J., Chavakis, T., Joosten, L. A. B., & Toonen, E. J. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.005 · Cited by 144 · see citing works
Echinatin effectively protects against NLRP3 inflammasome–driven diseases by targeting HSP90
Xu, G., Fu, S., Zhan, X., Wang, Z., Zhang, P., Shi, W., Qin, N., Chen, Y., Wang, C., Niu, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134601 · Cited by 143 · see citing works
Petrescu, M. D., Vlaicu, S. I., Ciumărnean, L., Milaciu, M. V., Mărginean, C., Florea, M., Vesa, Ș. C., & Popa, M. (2022) · Medicina · doi:10.3390/medicina58050641 · Cited by 150 · see citing works
Li, Z., Wang, F., Liang, B., Su, Y., Sun, S., Xia, S., Shao, J., Zhang, Z., Hong, M., Zhang, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00349-7 · Cited by 144 · see citing works
NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders
Ramachandran, R., Manan, A., Kim, J., & Choi, S. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01261-8 · Cited by 142 · see citing works
Yahoo, N., Dudek, M., Knolle, P. A., & Heikenwälder, M. F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.033 · Cited by 145 · see citing works
Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2
Ganguly, S., Rosenthal, S. B., Ishizuka, K., Troutman, T. D., Rohm, T. V., Khader, N., Aleman-Muench, G., Sano, Y., Archilei, S., Soroosh, P., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2405746121 · Cited by 145 · see citing works
“Inflammasome activation is a hallmark of MASH livers ( 42 ), and we found that TREM2 restrains NLRP3 inflammasome activation.”
Self-citationImmunopathobiology and therapeutic targets related to cytokines in liver diseases
He, Y., Hwang, S., Ahmed, Y. A., Feng, D., Li, N., Ribeiro, M. D. C., Lafdil, F., Kisseleva, T., Szabó, G., & Gao, B. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00580-w · Cited by 136 · see citing works
Emerging Role of Mitochondrial DNA as a Major Driver of Inflammation and Disease Progression
Zhong, F., Liang, S., & Zhong, Z. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.10.008 · Cited by 133 · see citing works
Chen, S., Tang, C., Ding, H., Wang, Z., Liu, X., Chai, Y., Jiang, W., Han, Y., & Zeng, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594071 · Cited by 132 · see citing works
Pathogenesis of NASH: the Impact of Multiple Pathways
Noureddin, M., & Sanyal, A. J. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0425-7 · Cited by 135 · see citing works
Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release
Pan, J., Ou, Z., Cai, C., Li, P., Gong, J., Ruan, X. Z., & He, K. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.08.006 · Cited by 132 · see citing works
Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?
Khanam, A., Saleeb, P. G., & Kottilil, S. (2021) · Cells · doi:10.3390/cells10051097 · Cited by 132 · see citing works
Mathur, A., Feng, S., Hayward, J. A., Ngo, C., Fox, D., Atmosukarto, I. I., Price, J. D., Schauer, K., Märtlbauer, E. P., Robertson, A. A. B., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0318-0 · Cited by 131 · see citing works
Self-citationWang, Z., Xu, G., Gao, Y., Zhan, X., Qin, N., Fu, S., Li, R., Niu, M., Wang, J., Liu, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.02.003 · Cited by 129 · see citing works
The Influence of Sex Hormones in Liver Function and Disease
Kasarinaite, A., Sinton, M. C., Saunders, P. T. K., & Hay, D. C. (2023) · Cells · doi:10.3390/cells12121604 · Cited by 134 · see citing works
The gasdermin family: emerging therapeutic targets in diseases
Zhu, C., Xu, S., Jiang, R., Yu, Y., Bian, J., & Zou, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01801-8 · Cited by 139 · see citing works
Danger signals in liver injury and restoration of homeostasis
Han, H., Desert, R., Das, S., Song, Z., Athavale, D., Ge, X., & Nieto, N. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.033 · Cited by 127 · see citing works
- Authors
- Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., Masters, S. L., Schroder, K., Cooper, M. A., Feldstein, A. E., & Farrell, G. C.
- Affiliations
- Australian National University (AU)
- University of California San Diego (US)
- The University of Queensland (AU)
- University of Washington (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Farrell, Geoffrey C.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 66
- Issue
- 5
- Pages
- 1037-1046
- ISSN
- 0168-8278 (ISSN-L)
- PMC
- PMC6536116
- OpenAlex
- W2585046292
- Cited by
- 1,110
- References
- 49
- Citations by year
- 2026: 117 · 2025: 147 · 2024: 126 · 2023: 150 · 2022: 160 · 2021: 143 · 2020: 121 · 2019: 61 · 2018: 70 · 2017: 14
- FWCI
- 57.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- ANU Open Research (Australian National University) (submittedVersion, cc-by-nc-nd)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (U01AA022489, R21AA023574)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK113592)
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- NLRP3 inflammasome, MCC950, nonalcoholic steatohepatitis, liver fibrosis, liver inflammation, IL-1β, caspase-1, cholesterol crystals, Kupffer cells, macrophages, neutrophil migration, methionine-choline-deficient diet, atherogenic diet, myeloid cells
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Disease Models, Animal, Female, Furans, Hepatitis, Heterocyclic Compounds, 4 or More Rings, Indenes, Liver Cirrhosis, Experimental, Sulfonamides, Sulfones, NF-kappa B, Reactive Oxygen Species, Mice, Interleukin-1beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
